Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)


Age Group
0-9 years 10-17 years 18-26 years


Biological treatment cell Biological
CTL019 T-cells
Trial Summary & Details
Ages: 3 Years to 21 Years
Condition: B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are refractory to standard chemotherapy regimen or relapsed after allogeneic stem cell transplant.

Active not recruiting
Childrens Hospital Los Angeles, Los Angeles, CA
Stanford University Medical Center, Palo Alto, CA
Children's Healthcare of Atlanta, Atlanta, GA
University of Michigan, Ann Arbor, MI
University of Minnesota Medical Center, Minneapolis, MN
Mercy Children's Kansas University, Kansas City, MO
Duke University Medical Center, Durham, NC
Cincinnati Children's Hospital, Cincinnati, OH
Oregon Health and Science University SC, Portland, OR
Children's Hospital of Philadelphia (CHOP), Philadelphia, PA
University of Texas Southwestern Medical Center SC, Dallas, TX
University of Utah, Salt Lake City, UT
University of Wisconsin Hospital and Clinics, Madison, WI

Novartis Pharmaceuticals
Not available.